OSG — Octave Specialty Group, Inc.

Summary of OSG Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: OSG reported a net loss of $30 million, or $0.84 per share, compared to a loss of $22 million, or $0.56 per share, in Q4 2024.
• Adjusted EBITDA: Increased to $1.4 million from $0.5 million year-over-year, driven by growth in the Insurance Distribution segment and reduced corporate expenses.
• Total Revenues: Rose 5% to just under $47 million, impacted by lower profit commissions and foreign exchange gains.
• Insurance Distribution Segment: Grew premium production by 9% and commission revenue by 13%, with organic revenue growth exceeding 8%.
• Everspan Performance: Gross premiums written increased 34%, with a combined ratio below 100% for the first time this year.

2. Strategic Updates and Business Highlights

• Standalone Operations: Q4 2025 marked the first full quarter as a standalone specialty insurance platform following a strategic transformation.
• Acquisition of ArmadaCare: Enhanced product diversification and added scale, contributing to recurring revenue streams with EBITDA margins over 40%.
• Launch of 1889 Specialty: A new MGA focused on management liability and professional lines for SME financial institutions.
• AI Integration: The company is implementing AI-driven tools to improve risk selection and operational efficiency, exemplified by the launch of Hammurabi, a proprietary AI platform for medical stop-loss business.

3. Forward Guidance and Outlook

• 2026 Expectations:
  • Insurance Distribution Segment: Anticipates organic revenue growth of at least 20% and adjusted EBITDA of approximately $40 million.
  • Specialty Insurance Segment (Everspan): Forecasts gross written premiums of around $410 million and adjusted EBITDA of about $7.5 million.
  • Corporate Adjusted Expenses: Expected to be below $30 million.
  • Consolidated Adjusted Net Income: Projected at around $0.50 per share for 2026.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The higher loss in Q4 2025 was attributed to acquisition costs, exit from the financial guarantee business, and an impairment of a legacy investment.
• G&A Ratio: Elevated at 11.7%, with expectations for reduction as the company scales.
• Negative EBITDA from Start-up MGAs: Six entities reported negative EBITDA, although most are expected to reach breakeven by Q4 2026.
• Market Challenges: The company faces a softening P&C market cycle and varying pricing dynamics across different segments, particularly in non-cat property and casualty lines.

5. Notable Q&A Insights

• Pipeline for New Start-ups: OSG is targeting 2 to 4 new MGAs per year, focusing on growth rather than the volume of launches.
• Cash Flow Expectations: Anticipated NCI buy-in costs for 2026 will be under $50 million, funded by cash and potential additional borrowing.
• Seasonality of Earnings: Earnings are expected to be weighted towards the first and fourth quarters, particularly for A&H businesses.
• Pricing Environment: Mixed dynamics were noted, with non-cat property seeing rate reductions of 5% to 10%, while casualty lines are experiencing stable or increasing rates, especially in excess casualty.

This summary encapsulates the key takeaways from the earnings call, highlighting both the positive developments and challenges faced by Octave Specialty Group as they navigate their growth strategy in 2026.